RT Journal Article
SR Electronic
T1 Serological signatures of SARS-CoV-2 infection: Implications for antibody-based diagnostics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.07.20093963
DO 10.1101/2020.05.07.20093963
A1 Rosado, Jason
A1 Pelleau, Stéphane
A1 Cockram, Charlotte
A1 Hélène Merkling, Sarah
A1 Nekkab, Narimane
A1 Demeret, Caroline
A1 Meola, Annalisa
A1 Kerneis, Solen
A1 Terrier, Benjamin
A1 Fafi-Kremer, Samira
A1 de Seze, Jerome
A1 Dejardin, François
A1 Petres, Stéphane
A1 Longley, Rhea
A1 Backovic, Marija
A1 Mueller, Ivo
A1 White, Michael T
YR 2020
UL http://medrxiv.org/content/early/2020/06/29/2020.05.07.20093963.abstract
AB Background Infection with SARS-CoV-2 induces an antibody response targeting multiple antigens that changes over time. This complexity presents challenges and opportunities for serological diagnostics.Methods A multiplex serological assay was developed to measure IgG and IgM antibody responses to seven SARS-CoV-2 spike or nucleoprotein antigens, two antigens for the nucleoproteins of the 229E and NL63 seasonal coronaviruses, and three non-coronavirus antigens. Antibodies were measured in serum samples from patients in French hospitals with RT-qPCR confirmed SARS-CoV-2 infection (n = 259), and negative control serum samples collected before the start of the SARS-CoV-2 epidemic (n = 335). A random forests algorithm was trained with the multiplex data to classify individuals with previous SARS-CoV-2 infection. A mathematical model of antibody kinetics informed by prior information from other coronaviruses was used to estimate time-varying antibody responses and assess the potential sensitivity and classification performance of serological diagnostics during the first year following symptom onset. A statistical estimator is presented that can provide estimates of seroprevalence in very low transmission settings.Results IgG antibody responses to trimeric Spike protein identified individuals with previous RT-qPCR confirmed SARS-CoV-2 infection with 91.6% sensitivity (95% confidence interval (CI); 87.5%, 94.5%) and 99.1% specificity (95% CI; 97.4%, 99.7%). Using a serological signature of IgG and IgM to multiple antigens, it was possible to identify infected individuals with 98.8% sensitivity (95% CI; 96.5%, 99.6%) and 99.3% specificity (95% CI; 97.6%, 99.8%). Informed by prior data from other coronaviruses, we estimate that one year following infection a monoplex assay with optimal anti-Stri IgG cutoff has 88.7% sensitivity (95% CI: 63.4%, 97.4%), and that a multiplex assay can increase sensitivity to 96.4% (95% CI: 80.9%, 100.0%). When applied to population-level serological surveys, statistical analysis of multiplex data allows estimation of seroprevalence levels less than 1%, below the false positivity rate of many other assays.Conclusion Serological signatures based on antibody responses to multiple antigens can provide accurate and robust serological classification of individuals with previous SARS-CoV-2 infection. This provides potential solutions to two pressing challenges for SARS-CoV-2 serological surveillance: classifying individuals who were infected greater than six months ago, and measuring seroprevalence in serological surveys in very low transmission settings.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis was not a clinical trialFunding StatementThis work was supported by the European Research Council (MultiSeroSurv ERC Starting Grant 852373; MW), l Agence Nationale de la Recherche and Fondation pour la Recherche Medicale (CorPopImm; MW), and the Institut Pasteur International Network (CoronaSeroSurv; MW). JR was supported by the Pasteur Paris University (PPU) International PhD Program. CC was supported by the European Research Council 771813.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Serum samples were obtained through the CORSER study (Etude sero-epidemiologique du virus SARS-CoV-2 en France : constitution d une collection d echantillons biologiques humains) directed by Institut Pasteur and approved by the Comite de Protection des Personnes Ile de France III, and the French COVID cohort (NCT04262921, sponsored by Inserm and approved by the Comite de Protection des Personnes Ile de France VI). Sample collection in Hopital Cochin was approved by the Research Ethics Commission of Necker-Cochin Hospital. Use of the Peruvian negative controls was approved by the Institutional Ethics Committee from the Universidad Peruana Cayetano Heredia (SIDISI 100873).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code used for reproducing the results is freely available on GitHub: https://github.com/MWhite-InstitutPasteur/SARS_CoV_2_SeroDX_phase2. https://github.com/MWhite-InstitutPasteur/SARS_CoV_2_SeroDX_phase2